300 related articles for article (PubMed ID: 21306638)
1. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
2. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
4. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
[TBL] [Abstract][Full Text] [Related]
5. Serological study in Tunisian cervical cancer patients.
Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
[TBL] [Abstract][Full Text] [Related]
6. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
[TBL] [Abstract][Full Text] [Related]
8. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins.
Sun Y; Shah KV; Müller M; Muñoz N; Bosch XF; Viscidi RP
J Clin Microbiol; 1994 Sep; 32(9):2216-20. PubMed ID: 7529250
[TBL] [Abstract][Full Text] [Related]
9. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
[TBL] [Abstract][Full Text] [Related]
10. Antibody response for L1, E6 and E7 HPV 16 and HPV 18 antigens in Tunisian women with cervical cancer and controls.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maalej M; Oueslati R
J Immunoassay Immunochem; 2008; 29(3):266-80. PubMed ID: 18569375
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
13. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
14. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
Marais D; Rose RC; Williamson AL
J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
[TBL] [Abstract][Full Text] [Related]
15. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Walboomers JM; Meijer CJ; Shah KV; Clayman B; Viscidi RP
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):935-40. PubMed ID: 10548324
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
[TBL] [Abstract][Full Text] [Related]
17. Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias.
Sasagawa T; Inoue M; Tanizawa O; Yutsudo M; Hakura A
Jpn J Cancer Res; 1992 Jul; 83(7):705-13. PubMed ID: 1325428
[TBL] [Abstract][Full Text] [Related]
18. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
19. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
20. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
